English
Regional settings| Spread | 0.07 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.98 |
| Open | 0.93 |
| 1-Year Change | 32.86% |
| Day's Range | 0.77 - 0.95 |
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing products for patients with cancer. The Company has created a targeted anti-cancer agent designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its pipeline includes two clinical-stage programs. ON 123300 product candidate is a multi-kinase inhibitor targeting cyclin dependent kinase (CDK 4/6) and other tyrosine kinasesto to drive tumor proliferation. Its another product candidate Oral Rigosertib in combination with a PD-1 inhibitor targeting patients with K-Ras mutated non-small cell lung cancer (NSCLC).
BRIEF: For the fiscal year ended 31 December 2021, Onconova Therapeutics Inc revenues decreased 2% to $226K. Net loss decreased 36% to $16.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Change in fair value of warrant liab. increase from $208K (expense) to $321K (income).
Common Stock $0.01 Par, 07/13, 80M Auth., 20,062,996 Issd,. Insiders Owns Approx.76.99%
